Pharmacokinetics of orally administered simvastatin in turkeys

• Autorzy: Jasiecka A. , Grabowski T. , Maslanka T. , Ziolkowski H. , Jaroszewski J. J.
• Języki publikacji: EN

Abstrakty

EN

The aim of the present study was to determine the pharmacokinetics of simvastatin (SIM) administered orally in 6-week-old turkeys at a single dose of 2 mg/kg b.w. The SIM concentrations in plasma were determined by validated HPLC-MS/MS method. Mean (± SD; n = 10) values of pharmacokinetic parameters evaluated were as follows: Cmax = 0.49 ± 0.21 ng/ml, tmax = 1.6 ± 1.1 h, AUC(0-∞) = 1.08 ± 0.57 h×ng/ml, t1/2kel = 2.14 ± 1.3 h and MRT = 3.08 ± 1.52 h. The results indicate that the SIM is absorbed from the gastrointestinal tract of turkeys; however, achieved plasma level is lower compared to those observed in mammals.

• Wydawca: -
• Czasopismo: Polish Journal of Veterinary Sciences
• Rocznik: 2013
• Tom: 16
• Numer: 2
• Opis fizyczny: p.377-379,fig.,ref.

Twórcy

autor

Jasiecka A.

• Departament of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Warmia and Mazury, Oczapowskiego 13, 10-718 Olsztyn, Poland

autor

Grabowski T.

• Polpharma Biologics, Trzy Lipy 3, 80-172 Gdańsk, Poland

autor

Maslanka T.

• Departament of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Warmia and Mazury, Oczapowskiego 13, 10-718 Olsztyn, Poland

autor

Ziolkowski H.

• Departament of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Warmia and Mazury, Oczapowskiego 13, 10-718 Olsztyn, Poland

autor

Jaroszewski J. J.

• Departament of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Warmia and Mazury, Oczapowskiego 13, 10-718 Olsztyn, Poland

Bibliografia

• Cermak R, Wein S, Wolffram S, Langguth P (2009) Effects of the flavonol quercetin on the bioavailability of simvastatin in pigs. Eur J Pharm Sci 38: 519-524.
• Elkin RG, Yan Z, Zhong Y, Donkin SS, Buhman KK, Story JA, Turek JJ, Porter RE Jr, Anderson M, Homan R, Newton RS (1999) Select 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors vary in their ability to reduce egg yolk cholesterol levels in laying hens through alteration of hepatic cholesterol biosynthesis and plasma VLDL composition. J Nutr 129: 1010-1019.
• FDA and CDER. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, MD (2001).
• Jang SB, Lee YJ, Lim LA, Park KM, Kwon BJ, Woo JS, Kim YI, Park MS, Kim KH, Park K (2010) Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. Clin Ther 32: 206-216.
• Lupattelli G, Siepi D, De Vuono S, Roscini AR, Crisanti F, Covelli D, Pirro M, Mannarino E (2012) Cholesterol metabolism differs after statin therapy according to the type of hyperlipemia. Life Sci 90: 846-850.
• Najib NM, Idkaidek N, Adel A, Admour I, Astigarraga RE, Nucci GD, Alam SM, Dham R, Qumaruzaman (2003) Pharmacokinetics and bioequivalence evaluation of two simvastatin 40 mg tablets (Simvast and Zocor) in healthy human volunteers. Biopharm Drug Dispos 24: 183-189.